Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475605 · ClinicalTrials.gov registry record
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
A clinical trial, sponsored by LEO Pharma.
- Terminated
- Registry status
- 8,071
- Enrollment target
NCT00475605: Clinical Trial study, sponsored by LEO Pharma.
NCT00475605 is a clinical trial that was terminated before completion, run by LEO Pharma. The registered enrollment target is 8,071 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475605 was terminated before completion, sponsored by LEO Pharma.
- TERMINATED
- Registry status
- 8,071 participants
- Enrollment target
Study Summary
This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were \< 16 years at the time of first tacrolimus ointment exposure are eligible to participate. No drug is distributed during this observational trial.
Primary Outcome
Standardised Incidence Ratio (versus population cancer rates)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,071 participants |
| Start Date | 2005-05-25 |
| Est. Completion | 2019-01-31 |
Why NCT00475605 stopped before completion
NCT00475605 is an observational study that tracks outcomes without assigning an intervention. Its 8,071 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00475605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00475605 about?
NCT00475605 is a clinical study titled "A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis". This is an observational study to assess the long-term safety of Protopic® Ointment for the treatment of atopic dermatitis. Patients whose ages are/were \< 16 years at the time of first tacrolimus ointment exposure are eligible to participate. No drug is distributed during this observational trial.
What is the current status of trial NCT00475605?
This trial is currently terminated. The enrollment target is 8,071 participants. The study started on 2005-05-25. Estimated completion is 2019-01-31.
Who is sponsoring clinical trial NCT00475605?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05593484 · 8,060 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska
- NCT06184945 · 8,100 participants · NA
Behavioral Economic & Staffing Strategies in the ICU
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- NCT00898638 · 8,000 participants
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI